Literature DB >> 15778242

Close association between valvar heart disease and central nervous system manifestations in the antiphospholipid syndrome.

I Krause1, S Lev, A Fraser, M Blank, M Lorber, L Stojanovich, J Rovensky, J Chapman, Y Shoenfeld.   

Abstract

BACKGROUND: Heart valves lesions and central nervous system involvement are among the most common manifestations of the antiphospholipid syndrome (APS).
OBJECTIVE: To evaluate possible interrelations between these manifestations in a large group of APS patients.
METHODS: 284 APS patients were evaluated retrospectively, 159 of whom had primary APS. Cardiac-CNS associations were determined for the entire study population, and for subgroups of patients with primary APS or APS associated with systemic lupus erythematosus (SLE).
RESULTS: Significant associations where found between cardiac vegetations and epilepsy (p < 0.02), and between cardiac valve thickening or dysfunction and migraine (p = 0.002). Borderline association was found between valvar vegetations and migraine (p = 0.09). A significant association was also found between all valvar lesions and stroke or transient ischaemic attacks. Subanalyses showed that patients with primary APS had significant associations between cardiac valve pathology and all CNS manifestations, while patients with APS associated with SLE had no such associations.
CONCLUSIONS: The study suggests potential differences in biological behaviour between primary APS and APS associated with SLE. The presence of cardiac valve pathology may be a risk factor for several types of CNS involvement in PAPS.

Entities:  

Mesh:

Year:  2005        PMID: 15778242      PMCID: PMC1755247          DOI: 10.1136/ard.2004.032813

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  32 in total

Review 1.  Non-stroke neurological syndromes associated with antiphospholipid antibodies: evaluation of clinical and experimental studies.

Authors:  J Chapman; J H Rand; R L Brey; S R Levine; I Blatt; M A Khamashta; Y Shoenfeld
Journal:  Lupus       Date:  2003       Impact factor: 2.911

2.  The antiphospholipid story.

Authors:  Donato Alarcón-Segovia
Journal:  J Rheumatol       Date:  2003-09       Impact factor: 4.666

3.  Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus. A prospective analysis of 500 consecutive patients.

Authors:  D Alarcón-Segovia; M Delezé; C V Oria; J Sánchez-Guerrero; L Gómez-Pacheco; J Cabiedes; L Fernández; S Ponce de León
Journal:  Medicine (Baltimore)       Date:  1989-11       Impact factor: 1.889

4.  The anticardiolipin syndrome.

Authors:  G R Hughes; N N Harris; A E Gharavi
Journal:  J Rheumatol       Date:  1986-06       Impact factor: 4.666

5.  The "primary" antiphospholipid syndrome: major clinical and serological features.

Authors:  R A Asherson; M A Khamashta; J Ordi-Ros; R H Derksen; S J Machin; J Barquinero; H H Outt; E N Harris; M Vilardell-Torres; G R Hughes
Journal:  Medicine (Baltimore)       Date:  1989-11       Impact factor: 1.889

Review 6.  Migraine, memory loss, and "multiple sclerosis ". Neurological features of the antiphospholipid (Hughes') syndrome.

Authors:  G R V Hughes
Journal:  Postgrad Med J       Date:  2003-02       Impact factor: 2.401

Review 7.  Mitral valve vegetation and cerebral emboli in a primary antiphospholipid syndrome patient who had hepatitis C virus infection: report of a case and review of the literature.

Authors:  O N Pamuk; N Cakir; M Soy; M Aktoz; Y Celik; O Akdemir
Journal:  Clin Rheumatol       Date:  2003-05       Impact factor: 2.980

8.  Features associated with epilepsy in the antiphospholipid syndrome.

Authors:  Yehuda Shoenfeld; Shaul Lev; Ilan Blatt; Miri Blank; Joseph Font; Philipp von Landenberg; Nirit Lev; Joseph Zaech; Ricard Cervera; Jean-Charles Piette; Munther A Khamashta; Maria L Bertolaccini; Graham R V Hughes; Pierre Youinou; Pierre Luigi Meroni; Vittorio Pengo; J Delgado Alves; Angela Tincani; Gyula Szegedi; Gabriella Lakos; Gunnar Sturfelt; Andreas Jönsen; Takao Koike; Marielle Sanmarco; Amelia Ruffatti; Zdenka Ulcova-Gallova; Sonja Praprotnik; Blaz Rozman; Margalit Lorber; Joab Chapman; Peter J C van-Breda-Vriezman; Jan Damoiseaux
Journal:  J Rheumatol       Date:  2004-07       Impact factor: 4.666

9.  Valvular heart disease in the primary antiphospholipid syndrome.

Authors:  E Galve; J Ordi; J Barquinero; A Evangelista; M Vilardell; J Soler-Soler
Journal:  Ann Intern Med       Date:  1992-02-15       Impact factor: 25.391

10.  Cerebral ischemic events associated with endocarditis, retinal vascular disease, and lupus anticoagulant.

Authors:  J M Pope; C L Canny; D A Bell
Journal:  Am J Med       Date:  1991-03       Impact factor: 4.965

View more
  13 in total

Review 1.  Neurologic manifestations of the antiphospholipid syndrome: integrating molecular and clinical lessons.

Authors:  Eyal Muscal; Robin L Brey
Journal:  Curr Rheumatol Rep       Date:  2008-01       Impact factor: 4.592

2.  A high-risk laboratory profile of antiphospholipid antibodies and thrombosis is associated with a large number of extra-criteria manifestations in obstetric antiphospholipid syndrome.

Authors:  Sebastián Udry; José Omar Latino; Cristina Belizna; Silvia Perés Wingeyer; Diego Santiago Fernández Romero; Gabriela de Larrañaga
Journal:  Immunol Res       Date:  2019-12       Impact factor: 2.829

Review 3.  Non-stroke Central Neurologic Manifestations in Antiphospholipid Syndrome.

Authors:  Cécile M Yelnik; Elizabeth Kozora; Simone Appenzeller
Journal:  Curr Rheumatol Rep       Date:  2016-02       Impact factor: 4.592

4.  Association of annular calcification and aortic valve sclerosis with brain findings on magnetic resonance imaging in community dwelling older adults: the cardiovascular health study.

Authors:  Carlos J Rodriguez; Traci M Bartz; W T Longstreth; Jorge R Kizer; Eddy Barasch; Donald M Lloyd-Jones; John S Gottdiener
Journal:  J Am Coll Cardiol       Date:  2011-05-24       Impact factor: 24.094

5.  Definition and treatment approach of non-criteria clinical manifestations of antiphospholipid syndrome.

Authors:  Ayten Yazıcı
Journal:  Eur J Rheumatol       Date:  2020-10

Review 6.  Valvular heart disease in antiphospholipid syndrome.

Authors:  Stéphane Zuily; Olivier Huttin; Shirine Mohamed; Pierre-Yves Marie; Christine Selton-Suty; Denis Wahl
Journal:  Curr Rheumatol Rep       Date:  2013-04       Impact factor: 4.592

7.  Patent foramen ovale, cardiac valve thickening, and antiphospholipid antibodies as risk factors for subsequent vascular events: the PICSS-APASS study.

Authors:  Kumar Rajamani; Seemant Chaturvedi; Zhezhen Jin; Shunichi Homma; Robin L Brey; Barbara C Tilley; Ralph L Sacco; J L P Thompson; J P Mohr; Steven R Levine
Journal:  Stroke       Date:  2009-06-04       Impact factor: 7.914

Review 8.  The Heart and APS.

Authors:  Mary-Carmen Amigo
Journal:  Clin Rev Allergy Immunol       Date:  2007-04       Impact factor: 8.667

Review 9.  The Migraine-Stroke Connection.

Authors:  Mi Ji Lee; Chungbin Lee; Chin-Sang Chung
Journal:  J Stroke       Date:  2016-05-31       Impact factor: 6.967

10.  Complete Resolution of a Large Bicuspid Aortic Valve Thrombus with Anticoagulation in Primary Antiphospholipid Syndrome.

Authors:  Rayan Jo Rachwan; Ghassan E Daher; Jawad Fares; Rachoin Rachoin
Journal:  Front Cardiovasc Med       Date:  2017-09-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.